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ABSTRACT 22 
The CD69 type II C-type lectin is one of the earliest indicators of leukocyte activation 23 
acting in lymphocyte migration and cytokine secretion. CD69 expression in 24 
hematopoietic lineage undergoes rapid changes depending on the cell-lineage, the 25 
activation state or the localization of the cell where it is expressed, suggesting a 26 
complex and tightly controlled regulation. Here we provide new insights on the 27 
transcriptional regulation of CD69 gene in mammal species. Through in silico studies, 28 
we analyzed several regulatory features of the 4 upstream conserved non-coding 29 
sequences (CNS 1-4) previously described, confirming a major function of CNS2 in the 30 
transcriptional regulation of CD69. In addition, multiple transcription binding sites are 31 
identified in the CNS2 region by DNA cross-species conservation analysis. By 32 
functional approaches we defined a core region of 226 bp located within CNS2 as the 33 
main enhancer element of CD69 transcription in the hematopoietic cells analyzed. By 34 
chromatin immunoprecipitation, binding of RUNX1 to the core-CNS2 was shown in a T 35 
cell line. In addition, we found an activating but not essential role of RUNX1 in CD69 36 
gene transcription by site-directed mutagenesis and RNA silencing, probably through 37 
the interaction with this potent enhancer specifically in the hematopoietic lineage. In 38 
summary, in this study we contribute with new evidences to the landscape of the 39 
transcriptional regulation of the CD69 gene. 40 
41 
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1. INTRODUCTION  42 
CD69 is an inducible receptor expressed in leukocytes. It is rapidly upregulated on the 43 
membrane of lymphocytes upon stimulation, as it is observed in T cells after 1 hour of 44 
treatment with PMA
1
, while it reaches its maximum expression in myeloid populations 45 
in about 24 hours 
2-5
. This time-specific regulation of CD69 expression is suggested to 46 
be in part due to distinct transcriptional regulation mechanisms, since several cis-acting 47 
elements have previously been found in CD69 locus with lineage-specific effects on 48 
transcription 
6
. 49 
In the human and mouse CD69 promoters, regulatory elements binding NF-κB, AP-1, 50 
OCT, CREB and the Early Growth Response proteins (EGR) have been identified and 51 
proposed as responsible for inducible expression
7-10
. Apart from these, other cis-52 
regulatory regions have been identified previously in the CD69 locus
6, 11
: four upstream 53 
conserved non-coding sequences (CNS 1-4) and a non-conserved hypersensitivity site 54 
(HS) located within the first intron of the CD69 gene. It has been previously shown that 55 
the four CNS are regulatory regions being in open conformation and possessing marks 56 
of active transcription on histones in mouse lymphocytes
6
. It was also observed a 57 
differential regulation between T and B cells in transgenic mice bearing the hCD2 58 
reporter under the control of the CD69 promoter and different combinations of the 59 
CNSs  
6
. Although transcriptional studies confirmed CNS2 as a potent transcriptional 60 
enhancer; in transgenic mouse lines, the construct formed by CNS2 plus CNS1 plus 61 
promoter showed an inhibition of the transgene expression
6
.  62 
Here we further analyzed the role of CNS2 in CD69 gene transcription, defining 63 
specific regulatory elements within this region and identifying transcription factors 64 
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which probably intervene in the enhancer mechanism. For that purposes, we employed 65 
both in silico and experimental procedures.  66 
We performed data mining of predicted conserved Transcription Factor Binding Sites 67 
(TFBS) in CNS2, which permitted the finding of cis-acting elements on their basis of 68 
conservation during evolution 
12
. This method has been successfully applied to find 69 
regulatory elements in other immune inducible genes, such as   Interferon14. After 70 
comparing these results with data from ENCODE Consortium, we further analyzed the 71 
cis- and trans-acting elements of CNS2 by experimental means. These approaches 72 
allowed us to obtain new insights on the transcriptional regulation of CD69, such as the 73 
identification of a minimal enhancer sequence within CNS2 and the role of different 74 
transcription factors in this function. The attempt to delineate the function of RUNX1 in 75 
CD69 transcription regulation and the discussion of the results founded is presented.  76 
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2. MATERIALS & METHODS 77 
2.1. Data from ENCODE consortium 78 
Human open chromatin regions, histone H3K27Ac marks and transcription factor 79 
binding by Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) in 80 
different cell lines were obtained from the ENCODE Consortium 
152
 and displayed on 81 
the University of California-Santa Cruz (UCSC) Genome Browser 82 
(https://genome.ucsc.edu/ENCODE/). Input sequences employed from UCSC  83 
(https://genome-euro.ucsc.edu/cgi-bin/hgGateway/) were: Human 2009 chr12: 84 
9,902,000-9,953,000 (Supplementary Figure 1); Human 2009 chr12: 9.912.000-85 
9.920.000 (Figs. S2 and S4); Human 2009 chr12: 9,922,000-9,950,500 (Supplementary 86 
Figure 3 and Supplementary Figure 5). 87 
 88 
2.2. Identification of predicted conserved transcription factor binding sites (TFBSs) 89 
within CNS2 90 
Sequences of CNS2 for human (Homo sapiens), mouse (Mus musculus), rat (Rattus 91 
norvegicus), rhesus (Macaca mulatta), dog (Canis familiaris) and horse (Equus 92 
caballus) species, were downloaded from the online platform Vista-Point from the 93 
portal VISTA tools from comparative genomics 94 
(http://genome.lbl.gov/vista/index.shtml) using as base genome the human genome 95 
version March 2006 from the UCSC Genomic Browser website. These sequences were 96 
introduced into the application Genomatix DiAlign on the Genomatix website 97 
(http://www.genomatix.de/), and the output data were depicted as arrows indicating the 98 
binding sites over a plot of sequence conservation in mammals obtained from the UCSC 99 
Genome Browser (human Mar 2006: chr12: 9,808,600-9,809,300). 100 
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 101 
2.3. Plasmids 102 
Mouse CD69 promoter (-1 to -609, BAC clone RP24-188C4) was cloned into BglII and 103 
HindIII restriction enzyme (RE) cloning sites of the commercial luciferase vector pGL3 104 
basic (Promega). After that, CNS2 region (mouse 2010 chr6: 129,234,359-129,235,318) 105 
was cloned into KpnI and XhoI RE sites, introducing an EcoRI site by KpnI for further 106 
cloning. Modified CNS2 constructs containing single and double deletions were 107 
generated by overlap PCR 
16
 employing custom primers (Supplementary Table 1) and 108 
cloned into EcoRI and XhoI RE sites in the plasmid containing the CD69 promoter. 109 
 110 
2.4. Site-Directed Mutagenesis 111 
The kit QuikChange Lightning Site-Directed Mutagenesis kit (Agilent) was employed 112 
following manufacturer instructions using primers to perform the mutations shown in 113 
Supplementary Table 2. Every PCR product and DpnI digestion was checked by 114 
agarose gel electrophoresis previous to transformation in bacteria. 115 
 116 
2.5. Luciferase assays 117 
Jurkat T cells (5-7 x 10
5
), K562, U937 and C1R cells (2-3 x 10
5
) were transfected with 118 
1 µg of  modified firefly luciferase plasmid (purified with Plasmid Maxi Kit from 119 
Qiagen) plus 20 ng of pRL-TK (Renilla luciferase plasmid from Promega, to 120 
standardize the luciferase activity independently of the efficiency of transfection 121 
between samples) using Superfect (Qiagen) following manufacturer's protocol. RAJI 122 
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cells (5-7 x 10
5
) were transfected with 2 µg of firefly luciferase plasmid and 20 ng of 123 
renilla plasmid per condition employing 6 µl of X-tremeGENE 9 reagent from Roche. 124 
After transfection, cells were cultured at 37 ºC with 5% CO2 for 24 hours. Next, they 125 
were stimulated or not with 10 ng/ml of PMA and 500 ng/ml of Ionomycin, PMA alone 126 
or plate-bound anti-CD3 (clone OKT3; eBioscience) and anti-CD28 (clone CD28.2; 127 
eBioscience) mouse antibodies (plated at 5 μg/ml) or were mock incubated, for other 24 128 
hours. 48 h after transfection, cells were lysed using Passive Lysis Buffer (Promega) and 129 
luciferase activity (firefly/renilla) was measured with the Dual Luciferase Kit from 130 
Promega. 131 
 132 
2.6. Nucleofection 133 
RUNX1 RNA silencing experiments were performed using Cell Line Nucleofector® Kit 134 
V from Amaxa and siRNAs siRUNX1-59 (ref: s2459) and siNeg were from Ambion. 10
6
 135 
Jurkat cells were used per transfection. Cells were washed 3 times in 1x PBS and 136 
resuspended in 100 μl of Cell Line Nucleofector Solution V. Then 600 ng of siRUNX1 or 137 
siNeg were mixed with the cell suspension in an Amaxa certified cuvette and 138 
nucleofected applying the program X-05 in the Amaxa Nucleofector. After 10 min at 139 
room temperature, cells were harvested with 500 μl of pre-warmed complete medium 140 
rinsing the cuvette, transferred to a 6-well culture dish and incubated at 37 ºC and 5% 141 
CO2 for 24 hours in a final volume of 1 ml of complete medium. Next, cells were 142 
harvested or stimulated with 10 ng/ml of PMA plus 500 ng/ml of Ionomycin for 24 143 
extra hours. Effective RUNX1 silencing at 24 hours was confirmed by western blot. 144 
 145 
2.7. RNA extraction and Real-time PCR 146 
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Cells nucleofected for 24 hours (unstimulated) or nucleofected for 24 hours and then 147 
stimulated for 24 extra hours were washed in cold 1x PBS and resuspended in 350 μl of 148 
lysis buffer RP1 (Macherey-Nagel). RNA extraction was performed employing 149 
NucleoSpin® RNA/Protein kit from Macherey-Nagel following manufacturer directions. 150 
cDNA was synthesized using AMV Reverse Transcriptase from Promega according to 151 
manufacturer's instructions. Real-time PCR was performed using LightCycler
® 
152 
FastStart DNA Master
PLUS 
SYBR Green I from Roche. Relative quantification was 153 
carried out amplifying hCD69 and 18s RNA (housekeeping control gene). Primers for 154 
hCD69 amplify a 50nt-amplicon located between exons 1 and 2. The primers used 155 
were: hCD69_F:  5'-CAGTCCAACCCAGTGTTCCT-3';  156 
hCD69_R: 5'-CGTGTTGAGAAATGGGGACT-3';  157 
RNA18S_F:  5'-CTCAACACGGGAAACCTCAC-3';  158 
RNA18S_R:  5'-CGCTCCACCAACTAAGAACG-3'. A touch-down protocol 
17
 was 159 
employed to avoid unspecific DNA amplification.  160 
 161 
2.8. Chromatin Immunoprecipitation 162 
ChIP assay was performed as previously described 
18
. Briefly, chromatin from cross-163 
linked cells (20 x 10
6
 HL-60 cells and 70 x 10
6
 in Jurkat cells per condition) was 164 
sonicated, incubated overnight with goat anti-RUNX1 (C-19), rabbit anti-Elk-1 (I-20) 165 
(Santa Cruz Biotechnology, Inc.) and goat (RUNX1 IP) and rabbit (Elk-1 IP) anti-IgG 166 
antibodies (Sigma-Aldrich) in RIPA buffer, and precipitated with protein G/A-167 
Sepharose. Cross-linkage of the co-precipitated DNA-protein complexes was reversed, 168 
and DNA was used as a template for quantitative PCR (qPCR). Primers employed are 169 
shown in Supplementary Table 3. 170 
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 171 
2.9. Flow cytometry of human cell lines 172 
Staining was performed for 20 min at 4º C with PE-Cy7- or PE- conjugated anti-human 173 
CD69 antibody diluted in staining buffer (1x PBS supplemented with 2% of Fetal 174 
Bovine Serum and 2mM of EDTA). Samples were analyzed employing the flow 175 
cytometer FACSCanto (Becton Dickinson) and data was analyzed using FACSDiva 176 
software (Becton Dickinson).  177 
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3. RESULTS 178 
3.1. CNS2 is a relevant regulatory element in hematopoietic cells  179 
As a first approximation we performed data mining of several regulatory features of the 180 
different Conserved Non-Coding Sequences, CNS1-4, described in a previous work
6
 181 
(and figure 1), for distinct subpopulations of human cells 182 
(https://genome.ucsc.edu/ENCODE/). We observed that the chromatin in the four CNSs 183 
were accessible constitutively in the hematopoietic lineages, in agreement with the 184 
experimental results of our previous study
6
. Remarkably, the strength of the 185 
hypersensitivity signal is higher for CNS2 and CNS1-Promoter than for CNS3 and 186 
CNS4 (Figure 1). H3K27ac was also enriched at CNS2 in several hematopoietic cells 187 
lines consistent with its role as a potent enhacer. In addition,  CNS2 also bound the 188 
highest number of transcription factors  (Figure 2) when compared with CNS1, CNS3 189 
and CNS4   These data provides additional evidence on the relevance of CNS2 to be a 190 
cis- regulatory element in vivo. Also, most of the factors described to bind to the 191 
promoter region were also find to bind to CNS2, which further supports a regulatory 192 
interaction between both regions. 193 
Next we performed an in silico search with Genomatix program DiAlign plus TF to 194 
identify conserved TFBSs in the CNS2 region. This analysis identifies cis-acting 195 
elements on their basis of conservation during evolution 
12
, presumably due to the 196 
outcome of beneficial effects on species survival. It is based on the definition of a 197 
weight matrix pattern of probability for each family or subfamily of transcription factors 198 
to bind a specific sequence of DNA, representing the complete nucleotide statistical 199 
distribution for each single position of the binding sequence. For that purpose, we 200 
compared sequences of CNS2 from human, mouse, rat, rhesus, dog and horse species, 201 
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and displayed the data as arrows indicating the conserved TFBSs  (in 6 species black, in 202 
4 species grey) over a plot of human-mice sequence conservation from VISTA Browser 203 
(Figure 3). 
13
 We found several conserved TFBSs, most of them common to mouse and 204 
human and as expected, generally located in the most conserved regions in CNS2 205 
(Figure 3). Among the binding sites for transcription factors related to the immune 206 
function are the RAR-related orphan receptor alpha (RORα) 19 , RUNX 20-22 and the 207 
GA-binding protein alpha chain (GABPA) 
23, 24
 , and NFAT 
25, 26
, the Interferon 208 
regulatory factors (IRF) 
27
 and c-Rel 
28-30
 . Other conserved binding sites are for 209 
transcription factors related to general processes occurring after activation, like 210 
cytoskeletal rearrangement for proliferation, such as SRF, or are targeted by several 211 
pathways affected by the immune response, such as the E-twenty six-like factor 1 (Elk-212 
1), which is a target of the MAPK pathways 
31
. This analysis suggests that these TFBSs 213 
undergo a strong trend to be conserved along all the mammal class, implying that they 214 
may have important roles in CD69 gene regulation. As expected, some  predicted 215 
conserved TFBSs such as ELK1, GATA, SRF, RUNX and NFAT, were confirmed to 216 
bind to CNS2 obtained through CHIP assays from ENCODE data (Figure 2). 217 
 218 
3.2. Regions of CNS2 responsible for its transcriptional enhancer function  219 
CD69 receptor expression is upregulated in lymphocytes and other leukocytes
32 220 
(Supplementary Figure 1) upon stimulation. To test the importance of the TFBSs in the 221 
transcriptional regulation capacity of CNS2, we analyzed the influence of deletions of 222 
the regions designated A, B, C and D, corresponding to regions that contain grouped 223 
TFBSs in CNS2 (Figure 3 and 4a).  224 
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The major effect in the enhancer activity was observed when the region B (which 225 
contains TFBSs for RUNX1, GABPA and Elk-1) was eliminated, in unstimulated and 226 
stimulated Jurkat cells, reaching a significant 55% reduction in luciferase activity under 227 
PMA stimulation (Figure 4b). We observed a similar reduction in the enhancer capacity 228 
of CNS2 in the absence of the region B in the monocytic U937 and myeloid K562 229 
PMA-stimulated cell lines (Supplementary Figure 2). A smaller decrease of 230 
transcriptional activity with the construct lacking the region A was observed, with 231 
significant reductions in the unstimulated or antibody-stimulated Jurkat cell line (Figure 232 
4b). Transcriptional activity of the constructs lacking regions C or D was not 233 
significantly different from the activity of the construct with the complete CNS2 (Figure 234 
4b). 235 
As the single deletion of the region B in CNS2 showed an important reduction in its 236 
enhancer function, we tested afterwards double deletion of regions, combining the 237 
absence of the region B with the deletion of regions A, C or D (Figure 4c). The 238 
construct AB reduced significantly the enhancer function of CNS2, decreasing 239 
transcription levels down to the levels of the promoter alone either in the T (Figure 4c) 240 
or in the B cell lines assayed (Supplementary Figure 2a). These data suggests that the 241 
region core of 226 bp embracing the regions A and B constitutes the most potent 242 
functional enhancer of the CD69 promoter in lymphocytes. To confirm these results, the 243 
region of 226bp of CNS2 covering the regions A and B were cloned independently 244 
upstream the promoter and assayed for their enhancer capacity. Remarkably, the 245 
enhancement of transcriptional activity by the construct with the region A-B of 226 bp 246 
was similar to the activity of the complete CNS2 sequence (Figure 4d). Therefore, these 247 
results defined the region of 226 bp containing multiple conserved transcription factors 248 
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binding elements as a core region that facilitate a cooperative effect of transcription 249 
factors  occurring to produce the enhancement of CD69 transcription. 250 
 251 
3.3. RUNX1 and other transcription factors may cooperate in the enhancer activity of 252 
CNS2  253 
As the role of the RUNX transcription factors in thymocyte differentiation and in 254 
homeostasis of naive T cells has been described
33
, its possible role in transcriptional 255 
regulation of CD69 trough CNS2 was further studied.   First, the binding of RUNX1 to 256 
its conserved site in the region B of CNS2, was assayed by performing chromatin 257 
immunoprecipitation in hematopoietic cell lines. Indeed, we observed this binding 258 
(CNS2_RUNXBS) in Jurkat cell line after stimulation (Figure 5a). In addition, when 259 
RUNX1 is immunoprecipitated, the sequences of Elk TFBS was found enriched 260 
according with the proximity of RUNX and Elk transcription factors in the CNS2 261 
region. Elk-1 binding to its own conserved TFBS in CNS2 (CNS2_ELK1BS) was 262 
observed in an inducible manner but not enrichment of RUNX1 TFBS was detected 263 
(Figure 5b).  264 
To further investigate the role of RUNX1 and other different transcription factors 265 
possibly interacting with RUNX1 in CNS2 regulatory function, we tested the enhancer 266 
activity of different constructs mutated in several TFBSs within the core region of 267 
CNS2: RUNX, GABPA, SRF, RUNX plus SRF and RUNX plus SRF plus GABPA 268 
(Figure 6). No significant reduction of transcriptional activity was observed employing 269 
these constructs; suggesting that these transcription factor may be acting in a 270 
cooperative way. The only single mutation which produces in all experiments a 271 
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reduction  of the transcriptional activity is the RUNX binding site mutation (Figure 5), 272 
although not reached a statistically significance.  273 
We then analyzed if RUNX1 silencing affected CD69 transcription and expression in 274 
Jurkat cells. Indeed, CD69 mRNA levels were reduced when a silencer of RUNX1 275 
(siRUNX1) was employed compared to the use of a control silencer (siNeg). This 276 
reduction was observed in all the experiments performed (a total of 4) and resulted to be 277 
significant (Figure 7) when the cell were unstimulated, however no reduction was 278 
observed in stimulated cells (data not shown). Since RUNX1 binding was not observed 279 
in the CNS2 region in unstimulated cells, this data suggests that RUNX1 transcription 280 
factor may regulate steady state CD69 transcriptional levels independently of CNS2. 281 
Moreover, these data indicates that the different transcription factors are collaborating in 282 
the enhancement of CD69 transcription carried out by CNS2 and other regions. 283 
284 
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4. DISCUSSION 285 
In this work we provide new data on CD69 gene transcriptional regulation: the 286 
description of a potent core enhancer in hematopoietic lineages which is located within 287 
the conserved non-coding sequence CNS2, and data pointing to a cooperative role of the 288 
different transcription factors, such as RUNX1, in the enhancer function through this 289 
region. 290 
Data of chromatin accessibility and histone marks of active regulatory elements 291 
analyzed from ENCODE showed that the accessible regions match perfectly with the 292 
conserved non-coding sequences. Importantly, these open regions were mainly found in 293 
hematopoietic cell lines. The ones found in the promoter CNS1 and CNS2 had the 294 
highest signal in T and B lymphoid cells, an intermediate signal in erythroblastoid and 295 
progenitor cells and a moderate signal in myeloid cell lines. However, in non-296 
hematopoietic cell lines this accessibility was markedly reduced. Therefore patterns of 297 
CD69 expression correlate with levels of open chromatin, suggesting that the regulation 298 
of the chromatin accessibility is a first control point in the transcriptional regulation of 299 
CD69 gene. The high number of transcription factors which bind to CNS2 observed in 300 
the ChIP-seq data from ENCODE and our previous results
6
 point to this region as a 301 
different and relevant regulatory element in the regulation of CD69 transcription. In this 302 
work, we defined a region of 226 bp to be responsible of the enhancer role of CNS2 in 303 
different hematopoietic cells and analyzed the role of different transcription factors 304 
which bind to conserved sites within this core region. However, mutation of the 305 
different transcription binding sites did not result in any marked difference in the 306 
luciferase expression. This absence of effect may be due to redundancy of transcription 307 
factor complexes or due to limitations in the luciferase assay. Indeed, even though the 308 
luciferase assay have been widely used in cell lines to determine and characterize the 309 
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activity of  promoters and enhances effects in regulating genes, it may not reflect the 310 
enhancer activity and the chromatin loop activity that occurs in vivo.  311 
Although all known hematopoietic subpopulations show inducible expression of CD69 312 
under stimulation by different molecules, the magnitude and the timing of the 313 
expression differs considerably 
28
. This fact cannot be attributed to differences in the 314 
chromatin state of the different cell types, as their chromatin accessibility profiles, 315 
observed in both, the ENCODE data presented in this paper and in our previous data
6
, 316 
were very similar among them. Similarly, according to the results of our transcriptional 317 
studies, all the hematopoietic cell lines analyzed show the same pattern of enhancement 318 
of the transcriptional activity of CD69 promoter by CNS2. Therefore, the differences in 319 
CD69 expression must be caused by different types of regulation, such as the action of 320 
different transcription factors on the regulatory regions of CD69. This hypothesis 321 
correlates with the observation of RUNX1 binding at basal state and under stimulation 322 
to different types of cells (Figures 2 and 5). As CNS2 regulatory region must show an 323 
open chromatin conformation without stimuli, the presence of RUNX1 binding seems to 324 
be related to the CD69 transcriptional activity (see mRNA expression of these cells  at 325 
BioGPS). Similarly, the analysis of ELK1 binding to CNS2 in Jurkat cell line suggest it 326 
may playing a similar activating role as RUNX1 in transcription. 327 
It has not been previously reported a relation between the transcription factors analyzed 328 
here and the lymphocyte activation under stimuli (which promotes the rapid expression 329 
of CD69, but not exclusively). However, it was observed that RUNX1 is required for 330 
the positive selection of thymocytes 
33
, the time point when CD69 is starting to be 331 
expressed during the thymocyte development 
34
. Accordingly, conditional knockout 332 
mice of RUNX1 in CD4+ T cells show reduced expression of CD69 in thymocytes 
33
. 333 
Although these evidences do not reveal a direct regulation of RUNX1 over CD69 gene, 334 
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it is likely that RUNX1, and the transcription factors which are upregulated after 335 
activation, act over multiple gene targets which may include CD69. 336 
Currently, there are proposed several mechanisms of activating transcription by 337 
enhancers 
35
. Our results from the mutagenesis and the ChIP experiments point to the 338 
billboard mechanism as the most probable way of acting by the transcription factors 339 
which bind to the core region of CNS2. Acting through this mechanism, the 340 
transcription factors would be acting in a cooperative way, resulting in that any of them 341 
would be required, and their action would be additive. Accordingly, it was previously 342 
reported that RUNX1 forms highly stable protein-DNA complexes in cooperation with 343 
E-twenty six (Ets) family of transcription factors (which include Elk-1), with 344 
remarkably frequent binding to T-cell specific enhancers
36-39
. Specifically, RUNX1 and 345 
Elk-1 have been proved to upregulate the EVI1 gene 
40
. Besides the physical interaction 346 
of the transcription factors, the chromatin conformation may be conforming a chromatin 347 
loop 
41
, which has been frequently described for enhancers of several immune genes 
42-348 
44
. This is supported by the fact that the vast majority of transcription factors which bind 349 
to the promoter also bind to CNS2 in the hematopoietic cells studied in the ChIP 350 
experiment from ENCODE (Figure 2), although further evidences are required.  351 
Encompassing all these studies, we suggest a model of transcriptional regulation of the 352 
CD69 gene (Figure 8), where transcription is controlled at a first level by chromatin 353 
accessibility. In this model, in hematopoietic cells, CNS2, and more specifically its core 354 
region, plays a major role in the enhancement of the transcription, being RUNX1 a 355 
transcription factor which intervenes in that process in a positive manner, at least in T 356 
lymphocytes. Depending on the subpopulation of the hematopoietic cells, different 357 
transcription factors may be cooperating in the transcriptional regulation, giving 358 
specificity and making possible a finely tuned regulation of CD69 protein levels. This 359 
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model does not exclude post-transcriptional regulation and needs further experimental 360 
analyses assessing the relevance of the complex regulation of CD69 expression in 361 
immune cells. 362 
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6. FIGURE LEGENDS 559 
 560 
Figure 1. DNase hypersensitivity sites and active regulatory histone marks in intron I, 561 
promoter, CNS1,CNS2, CNS3 and CNS4 of CD69 gene for different cell lineages. 562 
VISTA plot of conservation human (base) to mouse sequences, where the curve shows 563 
the percentage of conservation (left); grey zones, conserved non-coding sequences 564 
(CNSs). Acetylation of Lysine 27 in histone 3 (H3K27Ac) marks from different human 565 
cell lines indicated on the left. Data extracted from ENCODE consortium and depicted 566 
in UCSC Browser, ENCODE DNase I hypersensitivity data, condensed and expanded, 567 
displayed for hematopoietic (GM12878, K562, CD20+, CD14+, CD34+, HL-60, Jurkat, 568 
Th1, Th2, Th17, Treg) and non hematopoietic cells (A549, HeLa S3, HepG2, HUVEC, 569 
MCF7, HSMM, H1hESC, NHEK, NHLF). Stronger signals are depicted in black and 570 
weaker in grey. Base genome sequence: Human Feb. 2009, chr12 9 905 000-9 950 000. 571 
 572 
Figure 2. ENCODE chromatin immunoprecipitation data for promoter, CNS1, CNS2, 573 
CNS3 and CNS4 of human CD69 gene. VISTA plot of conservation human (base) to 574 
mouse sequences, where the curve shows the percentage of conservation (left); grey 575 
zones, conserved non-coding sequences (CNSs). Base genome sequence: Human Feb. 576 
2009, chr12 9 905 000-9 950 000. ENCODE data is depicted through UCSC browser 577 
for TF binding obtained from ChIP. The darkness of the bars correlates with the 578 
intensity of the binding signal for each analysis. 579 
  580 
Figure 3. Identification of conserved transcription factor binding sites related to the 581 
immune response in CNS2. VISTA conservation plot showing human and mouse CNS2 582 
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sequences comparison. Human sequence position is shown on the x axis and percentage 583 
similarity to mouse sequence on the y axis. Above, arrows mark the conserved 584 
transcription factor binding sites found using Genomatix DiAlign (see Material & 585 
Methods) (black arrows, TFBS conserved in the 6 species studied: human, mouse, rat, 586 
rhesus, dog, horse; grey arrows, TFBS conserved in 4 or 5 of those species). Every 587 
numbered arrow correspond to a TFBS indicated on the legend (right), where 
1)
 588 
correspond to TFBS non conserved in mice and 
2)
 marks TFBS non-conserved in the 589 
human species (both in italic). Base sequence: human Mar 2006, chr12:9 808 600-9 809 590 
300. Below, Conserved TFBS identified in mouse CNS2, grouped in 4 regions as for 591 
human CNS2.  592 
 593 
Figure 4. The regions A and B are mainly responsible for the enhancer activity of 594 
CNS2. Jurkat cells were transfected with different modified pGL3 plasmids as indicated 595 
on the left. 24 hours later cells were stimulated or not with anti-mouse CD3 & anti-596 
mCD28 (a) or PMA/Ionomycin (a-c), and after 24 extra hours luciferase activity was 597 
measured. Data represent the mean activity of each construct respect to the luciferase 598 
activity of the Promoter alone (Prom, RLU = 1) for each condition. Error bars represent 599 
SEM of 3 experiments. Each condition in every experiment was performed in 600 
triplicates. Statistics are calculated by one-way ANOVA with Bonferroni pair 601 
comparison method, where: *, p< 0,05; **, p< 0,01; ***, p<0,001. RLU, Relative 602 
Luciferase Units. 603 
 604 
Figure 5. RUNX1 binds to its TFBS in CNS2 in the hematopoietic lineage. Chromatin 605 
immunoprecipitation with anti-RUNX1 (a) and anti-ELK1 (b) antibodies was 606 
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performed in untreated (“Unstim.”) or 24 hours PMA-stimulated (“PMA”) Jurkat cells. 607 
Analysis of the co-immunoprecipitated sequences was performed by quantitative PCR 608 
amplifying a region in the promoter (Prom), the conserved TFBS for RUNX in CNS2 609 
(CNS2_RUNXBS), the conserved TFBS for RUNX in CNS3 (CNS3_RUNXBS) and 610 
the conserved TFBS for ELK1 close to the RUNX binding site (CNS2_ELK1BS. qRT–611 
PCR results were calculated using the 2-ΔΔCt method, and they are presented as the 612 
fold enrichment of chromatin DNA precipitated by the specific antibody versus 613 
chromatin DNA precipitated by goat anti-IgG (for RUNX1) or rabbit anti- IgG (for 614 
ELK1), as control. Data represent the mean of three different quantitative measures per 615 
IP. 616 
 617 
Figure 6. Contribution of RUNX, GABPA and SRF transcription factor in A-B 618 
enhancer activity. Site-directed mutagenesis was designed for RUNX, GABPA, SRF 619 
binding sites or combinations of them in CNS2 and transfection of the mutated plasmids 620 
was performed into Jurkat cell line. Data are represented as Mean +/- SEM from 4 621 
different experiments. Each trasnfection in every experiment was performed in 622 
duplicates or triplicates. RLU, Relative Luciferase Units.  623 
 624 
Figure 7. Down-regulation of hCD69 mRNA after RUNX1 silencing. Jurkat cells were 625 
nucleofected with RNA silencer of human RUNX1 (siRUNX) or a control silencer 626 
(siNeg) for 24 h and then RNA was extracted and analyzed by Real-Time PCR. Data are 627 
presented as Mean ± SEM of 4 different experiments in which every transfection was 628 
performed in triplicate. The mean value of cuadriplicates for siNeg transfection was 629 
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given an RNA relative concentration value of "100” and the siRUNX1 values were 630 
calculated accordingly.  631 
 632 
Figure 8. Proposed model of action of CNS2 in the regulation of the transcription of 633 
CD69 gene. CNS2 is only accessible in the hematopoietic lineage, being the regions A 634 
and B responsible for most all the enhancer activity of CNS2 on CD69 promoter. 635 
RUNX transcription factor binding site participates in this activity but needs the action 636 
of other TF in their respective binding sites in A and B. Bottom, one possible 637 
mechanism of action of CNS2 and TF in enhancement of promoter activity which 638 
consist in the formation of a loop between the two regions with the TF forming a 639 
complex, interacting at the same time with both regions and enhancing the transcription. 640 
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